摘要
背景:胃肝样腺癌(HAS)被认为是一种罕见的原发性胃肿瘤,其特征是肝细胞癌样组织学。由于仅根据苏木精和伊红 (H&E) 染色的结果难以检测肝样分化,因此 HAS 经常导致与传统胃腺癌 (CGA) 的诊断混淆。 β-连环蛋白在肝细胞癌(HCC)中高表达,其参与肿瘤起始细胞的维持、耐药、肿瘤进展和转移。由于HAS确诊病例稀少,对β-catenin的研究较少。 目的:选择在我院确诊的14例患者。 方法:对14例患者的临床特征进行统计学研究,并采用免疫组织化学方法对病理标本进行分析。 结果:我们检测到 HAS 癌组织与正常组织之间 β-catenin (P = 0.000)、glypican3 (P = 0.019) 和 hepar-1 (P = 0.007) 的表达存在统计学显着差异。此外,发现HAS癌组织和正常组织中β-catenin的表达之间存在显着相关性(Pearson相关系数:0.686,P = 0.007)。同时,观察到β-catenin的表达与存活时间之间存在显着相关性(Spearman相关系数= - 0.482,P = 0.003)。然而,我们发现 β-catenin 的表达与肿瘤的分化程度和大小、年龄、性别、血清 AFP 水平、微浸润和转移无关(P > 0.05)。 结论:我们的研究结果确立了 β-catenin 作为一个有用的标志物,可以区分 HAS 和 CGA,并可能改善早期诊断,指导 HAS 患者的适当和及时治疗。
关键词: 胃癌、肝样癌、腺癌、β-连环蛋白、甲胎蛋白、肝细胞癌、常规胃腺癌。
Current Molecular Medicine
Title:Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach
Volume: 21 Issue: 8
关键词: 胃癌、肝样癌、腺癌、β-连环蛋白、甲胎蛋白、肝细胞癌、常规胃腺癌。
摘要:
Background: Hepatoid adenocarcinoma of the stomach (HAS) has been recognized as a rare primary gastric tumor characterized by hepatocellular carcinomalike histology. HAS often causes diagnostic confusion with conventional gastric adenocarcinoma (CGA) due to the difficulty to detect hepatoid differentiation solely based on findings from hematoxylin and eosin (H&E) staining. β-catenin is highly expressed in hepatocellular carcinoma (HCC), which is involved in the maintenance of tumor initiating cells, drug resistance, tumor progression, and metastasis. Due to the scarcity of confirmed cases of HAS, there are few studies on β-catenin.
Objective: 14 patients diagnosed in our hospital were selected.
Methods: The clinical characteristics of 14 patients were statistically studied, and pathological specimens were analyzed by immunohistochemistry.
Results: We detected statistically significant difference in the expression of β-catenin (P = 0.000), glypican3 (P = 0.019), and hepar-1 (P = 0.007) between HAS cancer tissues and normal tissues. Furthermore, a significant correlation was found between the expression of β-catenin in HAS cancer tissue and normal tissue (Pearson correlation coefficient: 0.686, P = 0.007). Meanwhile, a significant correlation was observed between the expression of β-catenin and survival time (Spearman correlation coefficient= - 0.482, P = 0.003). However, we found the expression of β-catenin did not correlate with the tumor differentiation and size, age, gender, serum AFP levels, microinvasion, and metastasis (P > 0.05).
Conclusion: Our findings establish β-catenin as a useful marker that can distinguish HAS from CGA and may improve the early diagnosis to guide the appropriate and timely treatment of HAS patients.
Export Options
About this article
Cite this article as:
Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach, Current Molecular Medicine 2021; 21 (8) . https://dx.doi.org/10.2174/0929867327666200522215607
DOI https://dx.doi.org/10.2174/0929867327666200522215607 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemical Connexin Impairment in the Developing Gonad Associated with Offspring Infertility
Current Medicinal Chemistry Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation
Current Topics in Medicinal Chemistry Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Absorption, Pharmacokinetics and Disposition Properties of Solid Lipid Nanoparticles (SLNs)
Current Drug Metabolism Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets Proteomics and Protein Analyses of Ovine and Caprine Body Fluids: Current Studies and Future Promises
Current Protein & Peptide Science Genistein Aglycone: A Dual Mode of Action Anti-Osteoporotic Soy Isoflavone Rebalancing Bone Turnover Towards Bone Formation
Current Medicinal Chemistry Nanotechnology as a Promising Strategy for Anticancer Drug Delivery
Current Drug Delivery Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Recent Advances, Issues and Patents on Medical Nanorobots
Recent Patents on Engineering Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Mechanism of Action of Limonene in Tumor Cells: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design In Vitro Drug Metabolism of Green Tea Catechins in Human, Monkey, Dog, Rat and Mouse Hepatocytes
Drug Metabolism Letters Antioxidant Components of Brassica Vegetables Including Turnip and the Influence of Processing and Storage on their Anti-oxidative Properties
Current Medicinal Chemistry Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal